AzTrials
AzTrials

Alzheimer DiseasePhase 3NCT00996918

A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients

A Phase 3 study testing Bapineuzumab 0.5 mg/kg and Bapineuzumab 1.0 m/kg in people with Alzheimer Disease, run by Pfizer at 82 sites in 17 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The purpose of this study is to assess the long-term safety and tolerability of bapineuzumab in subjects with Alzheimer Disease who participated in study 3133K1-3000 (NCT00667810). Over 250 sites will participate in over 26 countries. Subjects will receive bapineuzumab. Read more about this study

Who is it for?
Ages 51 years and older
Conditions the study is for
Alzheimer Disease
What is being tested?
Bapineuzumab 0.5 mg/kg and Bapineuzumab 1.0 m/kg
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
198 participants
Where
82 sitesin 17 countries
Study dates
Dec 2009to Nov 2012
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 51 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subject has completed study 3133K1-3000 and brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of Alzheimer Disease
  • Mini-Mental Status Examination (MMSE) >=10 at screening
  • Caregiver able to attend all clinic visits with subject

Who cannot join

  • Any medical or psychiatric contraindication or clinically significant abnormality that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and completion of the study or could preclude the evaluation of the subject's response.
  • Any significant brain MRI abnormality.
  • Use of any investigational drugs or devices, other than bapineuzumab within the last 60 days prior to screening

Trial locations and contacts

82 sites in 17 countries.

82 sites in 17 countries

Spain16 sites
  • Pfizer Investigational Site

    Barcelona, Barcelona, 08003

  • Pfizer Investigational Site

    Barcelona, Barcelona, 08014

  • Pfizer Investigational Site

    Barcelona, Barcelona, 08034

  • Pfizer Investigational Site

    Barcelona, Barcelona, 08041

  • Pfizer Investigational Site

    Burgos, Burgos, 09006

  • Pfizer Investigational Site

    Elche, Alicante, 03203

  • Pfizer Investigational Site

    Madrid, Madrid, 28006

  • Pfizer Investigational Site

    Madrid, Madrid, 28034

  • Pfizer Investigational Site

    Madrid, Madrid, 28040

  • Pfizer Investigational Site

    Madrid, Madrid, 28041

  • Pfizer Investigational Site

    Madrid, Madrid, 28046

  • Pfizer Investigational Site

    Madrid, 28006

  • Pfizer Investigational Site

    Palma de Mallorca, Balearic Islands, 07010

  • Pfizer Investigational Site

    Palma de Mallorca, Balearic Islands, 07014

  • Pfizer Investigational Site

    Plasencia, Caceres, 10600

  • Pfizer Investigational Site

    Terrassa, Barcelona, 08221

Other trials in Spain

France13 sites
  • Pfizer Investigational Site

    Caen, 14033

  • Pfizer Investigational Site

    Dijon, France, 21000

  • Pfizer Investigational Site

    Lille, France, 59037

  • Pfizer Investigational Site

    Marseille, France, 13000

  • Pfizer Investigational Site

    Marseille, 13885

  • Pfizer Investigational Site

    Montpellier, 34295

  • Pfizer Investigational Site

    Nantes - Saint Herblain, 44093

  • Pfizer Investigational Site

    Nice, 06000

  • Pfizer Investigational Site

    Paris, France, 75013

  • Pfizer Investigational Site

    Poitiers, 86021

  • Pfizer Investigational Site

    Rennes, 35000

  • Pfizer Investigational Site

    Rouen, 76031

  • Pfizer Investigational Site

    Toulouse, 31059

Other trials in France

Japan13 sites
  • Pfizer Investigational Site

    Aichi

  • Pfizer Investigational Site

    Chiba

  • Pfizer Investigational Site

    Fukuoka

  • Pfizer Investigational Site

    Hiroshima

  • Pfizer Investigational Site

    Hyōgo

  • Pfizer Investigational Site

    Kagawa

  • Pfizer Investigational Site

    Kanagawa

  • Pfizer Investigational Site

    Kyoto

  • Pfizer Investigational Site

    Nagano

  • Pfizer Investigational Site

    Okayama

  • Pfizer Investigational Site

    Osaka

  • Pfizer Investigational Site

    Shizuoka

  • Pfizer Investigational Site

    Tokyo

Other trials in Japan

United Kingdom9 sites
  • Pfizer Investigational Site

    Brighton, BN2 5BE

  • Pfizer Investigational Site

    Glasgow, G20 OXA

  • Pfizer Investigational Site

    London, London, SE5 9RS

  • Pfizer Investigational Site

    London, W6 8RF

  • Pfizer Investigational Site

    Newcastle upon Tyne, NE4 5PL

  • Pfizer Investigational Site

    Penarth, CF64 2XX

  • Pfizer Investigational Site

    Sheffield, S10 2JF

  • Pfizer Investigational Site

    Sheffield, S35 8QS

  • Pfizer Investigational Site

    Swindon, SN3 6BW

Other trials in United Kingdom

Australia5 sites
  • Pfizer Investigational Site

    Adelaide, South Australia, 5000

  • Pfizer Investigational Site

    Heidelberg Heights, Victoria, 3081

  • Pfizer Investigational Site

    Hornsby, New South Wales, 2077

  • Pfizer Investigational Site

    Nedlands, Western Australia, 6009

  • Pfizer Investigational Site

    Woodville South, South Australia, 5011

Other trials in Australia

Poland5 sites
  • Pfizer Investigational Site

    Bydgoszcz, 85-796

  • Pfizer Investigational Site

    Krakow, 31-531

  • Pfizer Investigational Site

    Poznan, Poland, 61-289

  • Pfizer Investigational Site

    Warsaw, 01-211

  • Pfizer Investigational Site

    Warsaw, 02-097

Other trials in Poland

Belgium3 sites
  • Pfizer Investigational Site

    Antwerp, 2020

  • Pfizer Investigational Site

    Brussels, 1200

  • Pfizer Investigational Site

    Edegem, 2650

Other trials in Belgium

Portugal3 sites
  • Pfizer Investigational Site

    Amadora, Amadora, 2700-276

  • Pfizer Investigational Site

    Coimbra, Coimbra District, 3000-075

  • Pfizer Investigational Site

    Lisbon, Lisbon District, 1649-028

Other trials in Portugal

Chile2 sites
  • Pfizer Investigational Site

    Santiago, Chile, 7530193

  • Pfizer Investigational Site

    Santiago, Chile, 7630000

Other trials in Chile

Finland2 sites
  • Pfizer Investigational Site

    Kuopio, FIN-70210

  • Pfizer Investigational Site

    Turku, 20520

Other trials in Finland

Italy2 sites
  • Pfizer Investigational Site

    Milan, 20133

  • Pfizer Investigational Site

    Roma, 00179

Other trials in Italy

Netherlands2 sites
  • Pfizer Investigational Site

    's-Hertogenbosch, 5223 GZ

  • Pfizer Investigational Site

    Leeuwarden, 8934 AD

Other trials in Netherlands

Slovakia2 sites
  • Pfizer Investigational Site

    Bratislava, 825 56

  • Pfizer Investigational Site

    Rimavská Sobota, 979 12

Other trials in Slovakia

South Africa2 sites
  • Pfizer Investigational Site

    Johannesburg, Gauteng, 2196

  • Pfizer Investigational Site

    Pretoria, Gauteng, 0081

Other trials in South Africa

New Zealand1 site
  • Pfizer Investigational Site

    North Shore, NZ, 622

Other trials in New Zealand

Sweden1 site
  • Pfizer Investigational Site

    Malmö, SE-205 02

Other trials in Sweden

Switzerland1 site
  • Pfizer Investigational Site

    Basel, Canton of Basel-City, CH-4031

Other trials in Switzerland

About this study

Official title: A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety And Tolerability Trial Of Bapineuzumab (AAB-001, ELN115727) In Subjects With Alzheimer Disease Who Are Apolipoprotein E e4 Noncarriers And Participated In Study 3133K1-3000

The purpose of this study is to assess the long-term safety and tolerability of bapineuzumab in subjects with Alzheimer Disease who participated in study 3133K1-3000 (NCT00667810). Over 250 sites will participate in over 26 countries. Subjects will receive bapineuzumab. Each subject's participation will last approximately 4 years.

Being tested
Bapineuzumab 0.5 mg/kg, Bapineuzumab 1.0 m/kg
Keywords
antibody
Medical subject headings
Alzheimer Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Bapineuzumab 0.5 mg/kgDrug

    Also called AAB-001

    Bapineuzumab I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.

  • Bapineuzumab 1.0 m/kgDrug

    Also called AAB-001

    I.V., 1.0 mg/kg, infusion every 13 weeks for a total of 16 infusions.

Study groups in NCT00996918
Study groupRoleWhat they receive
Bapineuzumab 0.5 mg/kgExperimentalbapineuzumab
Receives: Drug: Bapineuzumab 0.5 mg/kg
Bapineuzumab 1.0 m/kgExperimentalbapineuzumab
Receives: Drug: Bapineuzumab 1.0 m/kg

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants Reporting a Serious Adverse Event.

    Safety was measured according to standard adverse event collection as described in the Adverse Event Section of the Results. Complete tables of events are provided there.

    Measured: Up to Week 195

Secondary outcomes (8)
  1. Change From Base Study Baseline in Alzheimer's Disease Assesment Scale-Cognitive Subscale (ADAS-Cog/11) at Weeks 13, 26, 39, 52 and 78.

    The ADAS-Cog is a multi-item, objective measure of cognitive function. The scale evaluates memory, language, and praxis with items such as orientation, word recall, word recognition, object identification, comprehension, and the completion of simple tasks. Analysis of the ADAS-Cog for this study was based upon an 11 item score from the following items 1) word recall task, 2) naming objects and fingers, 3) following commands, 4) constructional praxis, 5) ideational praxis, 6) orientation, 7) word recognition, 8) remembering test instructions, 9) spoken language ability, 10) word finding difficulty in spontaneous speech, and 11) comprehension.This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced. The ADAS-Cog/11 ranged from 0 to 70 points, with higher scores indicating a greater degree of impairment. A negative change from baseline indicates a decrease in cognitive impairment.

    Measured: Weeks 13, 26, 39, 52 and 78

  2. Change From Extension Study Baseline in ADAS-Cog/11 at Weeks 13, 26, 39, 52 and 78.

    The ADAS-Cog is a multi-item, objective measure of cognitive function. The scale evaluates memory, language, and praxis with items such as orientation, word recall, word recognition, object identification, comprehension, and the completion of simple tasks. Analysis of the ADAS-Cog for this study was based upon an 11 item score from the following items 1) word recall task, 2) naming objects and fingers, 3) following commands, 4) constructional praxis, 5) ideational praxis, 6) orientation, 7) word recognition, 8) remembering test instructions, 9) spoken language ability, 10) word finding difficulty in spontaneous speech, and 11) comprehension.This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced. The ADAS-Cog/11 ranged from 0 to 70 points, with higher scores indicating a greater degree of impairment. A negative change from baseline indicates a decrease in cognitive impairment.

    Measured: Weeks 13, 26, 39, 52 and 78

  3. Change From Base Study Baseline in Disability Assessment for Dementia (DAD) Score at Weeks 13, 26, 39, 52 and 78.

    The DAD measures instrumental and basic activities of daily living in participants with Alzheimer's Disease (AD). The DAD is administered to the participants'caregiver in the form of an interview. This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced by the participant. This scale assesses a participants' ability to initiate, plan, and perform activities related to hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. Each item can be scored as 1 = yes, 0 = no, non applicable = NA. A total score is obtained by adding the rating for each question and converting this total score out of 100. Higher scores indicate better function; a positive change from baseline indicates an improvement

    Measured: Weeks 13, 26, 39, 52 and 78

  4. Change From Extension Study Baseline in DAD Score at Weeks 13, 26, 39, 52 and 78

    The DAD measures instrumental and basic activities of daily living in participants with AD. The DAD is administered to the participants'caregiver in the form of an interview. This scale had to be administered by a trained and certified psychometric rater who did not have access to any information regarding adverse events experienced by the participant. This scale assesses a participants' ability to initiate, plan, and perform activities related to hygiene, dressing, continence, eating, meal preparation, telephoning, going on an outing, finance and correspondence, medications, leisure, and housework. Each item can be scored as 1 = yes, 0 = no, non applicable = NA. A total score is obtained by adding the rating for each question and converting this total score out of 100. Higher scores indicate better function; a positive change from baseline indicates an improvement

    Measured: Weeks 13, 26, 39, 52 and 78

  5. Change From Base Study Baseline in Neuropsychiatric Inventory (NPI) Score at Weeks 26, 52 and 78.

    NPI:12-domain caregiver assessment of behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, appetite/eating, nighttime behavior. Severity (1=Mild to 3=Severe), frequency (1=occasionally to 4=very frequently) scales recorded for each domain; frequency*severity=each domain score(range 0-12). Total score=sum of each domain score (range 0-144); higher score=greater behavioral disturbances; negative change score from baseline=improvement.

    Measured: Weeks 26, 52 and 78

  6. Change From Extension Study Baseline in NPI Score at Weeks 26, 52 and 78.

    NPI:12-domain caregiver assessment of behavioral disturbances occurring in dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, appetite/eating, night-time behavior. Severity (1=Mild to 3=Severe), frequency (1=occasionally to 4=very frequently) scales recorded for each domain; frequency*severity=each domain score(range 0-12). Total score=sum of each domain score(range 0-144); higher score=greater behavioral disturbances; negative change score from baseline=improvement.

    Measured: Weeks 26, 52 and 78

  7. Change From Base Study Baseline in Mini-mental State Examination (MMSE) Score at Weeks 6, 19, 32, 45 and 78.

    MMSE measured general cognitive functioning: orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two intersecting polygons. Total score derived from sub-scores; total ranged from 0 to 30, higher score indicates better cognitive state.

    Measured: Weeks 6, 19, 32, 45 and 78

  8. Change From Extension Study Baseline in MMSE Score at Weeks 6, 19, 32, 45 and 78.

    MMSE measured general cognitive functioning: orientation, memory, attention, concentration, naming, repetition, comprehension, and ability to create a sentence and to copy two intersecting polygons. Total score derived from sub-scores; total ranged from 0 to 30, higher score indicates better cognitive state

    Measured: Weeks 6, 19, 32, 45 and 78

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Oct 2009 (estimated)
  2. Study startDec 2009
  3. Primary completionNov 2012
  4. Study completionNov 2012

Why it stopped: The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical benefit. This decision was not based on any new safety concerns.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
198 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00996918
Sponsor's protocol ID
3133K1-3002
Other IDs
B2521003
Status last verified
Nov 2013
First submitted
14 Oct 2009
Last updated
1 Jan 2014
Data monitoring committee
Yes

Publications

  • Ivanoiu A, Pariente J, Booth K, Lobello K, Luscan G, Hua L, Lucas P, Styren S, Yang L, Li D, Black RS, Brashear HR, McRae T. Long-term safety and tolerability of bapineuzumab in patients with Alzheimer's disease in two phase 3 extension studies. Alzheimers Res Ther. 2016 Jun 23;8(1):24. doi: 10.1186/s13195-016-0193-y.

    PubMed 27334799

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Bapineuzumab 0.5 mg/kg and Bapineuzumab 1.0 m/kg in people with Alzheimer Disease, run by Pfizer at 82 sites in 17 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 1 Jan 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 82 sites in Spain, France, Japan, United Kingdom, Australia and 12 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 1 Jan 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants Reporting a Serious Adverse Event. (time frame: Up to Week 195). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00996918, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jan 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in